To close this gap, Gupta et al. generated paclitaxel-resistant breast cancer cell lines by continuous drug exposure and identified the resistance to be dependent on the expression of the EGF-receptor HER2 [166], a well-known drug target that is frequently amplified or overexpressed in breast cancer. Here, ERBB2 is linked to breast carcinoma.